Results 171 to 180 of about 540,928 (304)

Correction: Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice

open access: yesCell Communication and Signaling, 2023
Anna Marlene Schmid   +20 more
doaj   +1 more source

Comparative assessment of cancer mortality of the population living in two territories under the influence of enterprises for the blister copper production

open access: yesSafety and Health at Work, 2022
Natalia Zlygosteva   +3 more
doaj   +1 more source

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

open access: yesArthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian   +111 more
wiley   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

open access: yesArthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman   +2 more
wiley   +1 more source

Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting –Adjusted Comparison to a Historical Control Group Treated With Belimumab

open access: yesArthritis &Rheumatology, EarlyView.
Objective The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC.
Chong Luo   +15 more
wiley   +1 more source

Nationwide temporal trends in adverse pregnancy outcomes and treatments in systemic lupus erythematosus pregnancy over two decades in Sweden

open access: yesArthritis &Rheumatology, Accepted Article.
Objective This nationwide descriptive study examined temporal trends in adverse pregnancy outcomes (APOs) and treatments in systemic lupus erythematosus (SLE) pregnancies in Sweden over 2003‐2022. Methods Using nationwide Swedish registers, we identified 1,417 pregnancies of women with prevalent SLE and delivery dates in 2003‐2022, and matched them to ...
Ngoc V. Nguyen   +6 more
wiley   +1 more source

The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Anti‐Neutrophil Cytoplasmic Antibody‐Associated Vasculitis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Ear, nose and throat (ENT) manifestations are common in ANCA‐associated vasculitis (AAV). There is unmet need for drugs to target these manifestations. Granuloma formation is characteristic of proteinase 3 (PR3)‐AAV. In a zebrafish model, niclosamide inhibits PR3‐induced granuloma formation.
Benjamin Lim   +4 more
wiley   +1 more source

Prescribing of medication to prevent glucocorticoid harms in patients with Polymyalgia Rheumatica: a cross‐sectional study and two emulated target trials in the Clinical Practice Research Datalink Aurum

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐ and gastro‐protective medications are recommended for those at high‐risk of adverse events from GCs but no trials have evaluated their effectiveness in PMR.
Helen Twohig   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy